Berberine suppresses metastasis and recurrence of hepatocellular carcinoma by targeting circulating tumour cells: abridged secondary publication

CS Cheng; HY Tan; C Zhang; YT Chan; ZJ Zhang; K Man; MF Yuen; N Wang; Y Feng

Berberine suppresses metastasis and recurrence of hepatocellular carcinoma by targeting circulating tumour cells: abridged secondary publication

CS Cheng
, HY Tan
, C Zhang
, YT Chan
, ZJ Zhang
, K Man
, MF Yuen
, N Wang
, Y Feng^*

^*Corresponding author for this work

Centre for Chinese Herbal Medicine Drug Development Limited

Research output: Contribution to journal › Journal article › peer-review

4 Citations (Scopus)

Abstract

1. In mice with hepatocellular carcinoma with and without surgical resection, a combination of berberine and sorafenib potently improved the therapeutic efficacy and outcome without major adverse effects.
2. In our mouse model, berberine suppressed the in vitro viability and presentation of CD44+EpCAM+ circulating tumour cells (CTCs), as berberine is associated with inhibition of the invasiveness and re-attachment of CTCs and induction of cell apoptosis.
3. The inhibitory effect of berberine on CTCs was due to suppressed expression of CD44 and epithelial-mesenchymal transition pathways in CTCs.

Original language	English
Pages (from-to)	10-11
Number of pages	2
Journal	Hong Kong Medical Journal
Volume	28
Issue number	6 (Supplement 6)
Publication status	Published - Dec 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

https://www.hkmj.org/system/files/hkmj2212sp6p10.pdf

Cite this

@article{3bef5347f80c41f09f7f364441713860,

title = "Berberine suppresses metastasis and recurrence of hepatocellular carcinoma by targeting circulating tumour cells: abridged secondary publication",

abstract = "1. In mice with hepatocellular carcinoma with and without surgical resection, a combination of berberine and sorafenib potently improved the therapeutic efficacy and outcome without major adverse effects. 2. In our mouse model, berberine suppressed the in vitro viability and presentation of CD44+EpCAM+ circulating tumour cells (CTCs), as berberine is associated with inhibition of the invasiveness and re-attachment of CTCs and induction of cell apoptosis. 3. The inhibitory effect of berberine on CTCs was due to suppressed expression of CD44 and epithelial-mesenchymal transition pathways in CTCs.",

author = "CS Cheng and HY Tan and C Zhang and YT Chan and ZJ Zhang and K Man and MF Yuen and N Wang and Y Feng",

note = "Funding information: This study was supported by the Health and Medical Research Fund, Health Bureau, Hong Kong SAR Government (\#16172751). The full report is available from the Health and Medical Research Fund website (https://rfs1.fhb.gov.hk/index.html). Publisher copyright: {\textcopyright} 2022 Administering Institution and Hong Kong SAR Government",

year = "2022",

month = dec,

language = "English",

volume = "28",

pages = "10--11",

journal = "Hong Kong Medical Journal",

issn = "1024-2708",

publisher = "Hong Kong Academy of Medicine Press",

number = "6 (Supplement 6)",

}

TY - JOUR

T1 - Berberine suppresses metastasis and recurrence of hepatocellular carcinoma by targeting circulating tumour cells

T2 - abridged secondary publication

AU - Cheng, CS

AU - Tan, HY

AU - Zhang, C

AU - Chan, YT

AU - Zhang, ZJ

AU - Man, K

AU - Yuen, MF

AU - Wang, N

AU - Feng, Y

N1 - Funding information: This study was supported by the Health and Medical Research Fund, Health Bureau, Hong Kong SAR Government (#16172751). The full report is available from the Health and Medical Research Fund website (https://rfs1.fhb.gov.hk/index.html). Publisher copyright: © 2022 Administering Institution and Hong Kong SAR Government

PY - 2022/12

Y1 - 2022/12

N2 - 1. In mice with hepatocellular carcinoma with and without surgical resection, a combination of berberine and sorafenib potently improved the therapeutic efficacy and outcome without major adverse effects. 2. In our mouse model, berberine suppressed the in vitro viability and presentation of CD44+EpCAM+ circulating tumour cells (CTCs), as berberine is associated with inhibition of the invasiveness and re-attachment of CTCs and induction of cell apoptosis. 3. The inhibitory effect of berberine on CTCs was due to suppressed expression of CD44 and epithelial-mesenchymal transition pathways in CTCs.

AB - 1. In mice with hepatocellular carcinoma with and without surgical resection, a combination of berberine and sorafenib potently improved the therapeutic efficacy and outcome without major adverse effects. 2. In our mouse model, berberine suppressed the in vitro viability and presentation of CD44+EpCAM+ circulating tumour cells (CTCs), as berberine is associated with inhibition of the invasiveness and re-attachment of CTCs and induction of cell apoptosis. 3. The inhibitory effect of berberine on CTCs was due to suppressed expression of CD44 and epithelial-mesenchymal transition pathways in CTCs.

UR - https://www.hkmj.org/abstracts/v28%20Suppl%206n6/10.htm

UR - https://www.scopus.com/pages/publications/85144268891

M3 - Journal article

C2 - 36535791

AN - SCOPUS:85144268891

SN - 1024-2708

VL - 28

SP - 10

EP - 11

JO - Hong Kong Medical Journal

JF - Hong Kong Medical Journal

IS - 6 (Supplement 6)

ER -

Berberine suppresses metastasis and recurrence of hepatocellular carcinoma by targeting circulating tumour cells: abridged secondary publication

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this